aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. aTyr Pharma, Inc. (NASDAQ:ATYR) was one of the stocks that was covered in that article. Wall Street analysts believe ATYR has a 485% upside potential over the next 12 months.

A pharmacist in a pharmacy preparing a prescription medication for a patient suffering from Fibromyalgia.

aTyr Pharma, Inc. (NASDAQ:ATYR) stands as a pioneering biotherapeutics company dedicated to discovering and developing innovative medicines targeting novel immunological pathways. Established in 2005, aTyr Pharma has carved out a niche in addressing the critical needs of patients suffering from interstitial lung diseases (ILDs), a group of disorders characterized by progressive scarring of lung tissues. Among its promising initiatives, the company’s lead therapeutic candidate, Efzofitimod, has emerged as a beacon of hope. Efzofitimod, a selective modulator of neuropilin-2 (NRP2), holds the potential to transform the treatment landscape for ILDs. Currently undergoing Phase III clinical trials, as well as Phase 1b/2a trials, Efzofitimod is designed to reduce inflammation and improve lung function, offering a possibility of reducing or even eliminating the need for corticosteroids, a significant advancement for patients who endure long-term side effects from these standard therapies.

The company’s commitment to advancing Efzofitimod has been bolstered by its strategic partnership with Kyorin Pharmaceutical Co., Ltd. This collaboration focuses on Efzofitimod’s development and commercialization in Japan, enabling aTyr Pharma to leverage Kyorin’s established presence and resources within the Japanese market while simultaneously concentrating its efforts on operations in the United States. Such global partnerships underscore aTyr Pharma’s forward-thinking approach to expanding its reach and ensuring the accessibility of its groundbreaking treatments.

In addition to its clinical endeavors, aTyr Pharma, Inc. (NASDAQ:ATYR) has a robust cash position of $88 million that provides a solid foundation for continued innovation and expansion. Analysts are optimistic about the stock, with 63% recommending it as a “Strong Buy” and the remainder holding a “Buy” position. Reflecting this confidence, the consensus amongst analysts pegs the average share price at $18.55 over the next twelve months, marking an upside potential of 485.17%.

Overall, aTyr Pharma, Inc. (NASDAQ:ATYR) ranks 6th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of ATYR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than ATYR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy

Disclosure: None. This article is originally published at Insider Monkey.